JP2008515801A - モルヒネおよびモルヒネ前駆体 - Google Patents

モルヒネおよびモルヒネ前駆体 Download PDF

Info

Publication number
JP2008515801A
JP2008515801A JP2007534882A JP2007534882A JP2008515801A JP 2008515801 A JP2008515801 A JP 2008515801A JP 2007534882 A JP2007534882 A JP 2007534882A JP 2007534882 A JP2007534882 A JP 2007534882A JP 2008515801 A JP2008515801 A JP 2008515801A
Authority
JP
Japan
Prior art keywords
morphine
composition
mammal
administered
composition comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007534882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008515801A5 (https=
Inventor
ジョージ ビー． ステファノ
パトリック カデット
カーク ジェイ． マンティオン
ウェイ ジュ
Original Assignee
ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク filed Critical ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク
Publication of JP2008515801A publication Critical patent/JP2008515801A/ja
Publication of JP2008515801A5 publication Critical patent/JP2008515801A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
JP2007534882A 2004-10-01 2005-09-30 モルヒネおよびモルヒネ前駆体 Pending JP2008515801A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61504804P 2004-10-01 2004-10-01
US71476905P 2005-09-06 2005-09-06
PCT/US2005/035628 WO2006039691A2 (en) 2004-10-01 2005-09-30 Morphine and morphine precursors

Publications (2)

Publication Number Publication Date
JP2008515801A true JP2008515801A (ja) 2008-05-15
JP2008515801A5 JP2008515801A5 (https=) 2008-11-13

Family

ID=36143157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007534882A Pending JP2008515801A (ja) 2004-10-01 2005-09-30 モルヒネおよびモルヒネ前駆体

Country Status (6)

Country Link
US (6) US20080221143A1 (https=)
EP (1) EP1809283A2 (https=)
JP (1) JP2008515801A (https=)
AU (1) AU2005292184A1 (https=)
CA (1) CA2582346A1 (https=)
WO (1) WO2006039691A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018511639A (ja) * 2015-04-14 2018-04-26 スティーブン・ホフマン 自閉症を治療するための組成物及び方法
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US10857118B2 (en) 2013-10-22 2020-12-08 Yamo Pharmaceuticals Llc Compositions and methods for treating intestinal hyperpermeability
US12150924B2 (en) 2018-07-19 2024-11-26 Yamo Pharmaceuticals Llc Compositions and methods for treating autism

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2582346A1 (en) 2004-10-01 2006-04-13 The Research Foundation Of State University Of New York Morphine and morphine precursors
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
CN101766622A (zh) * 2009-12-16 2010-07-07 昆明理工大学 Morphine作为保护PC12细胞免于帕金森病毒性物损伤剂的应用
EP2640358B1 (en) * 2010-11-15 2018-01-03 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
ES2967693T3 (es) 2014-03-13 2024-05-03 Neuroderm Ltd Composiciones del inhibidor de la dopa descarboxilasa
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
MX2021008821A (es) 2019-01-25 2021-08-24 Avedro Inc Derivados de bis (diazirina) como foto-reticulante para el tratamiento de trastornos ectasicos de cornea.
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894027A (en) * 1973-07-31 1975-07-08 Merck & Co Inc Resolution of racemic reticuline and racemization of its enantiomers
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US5116847A (en) * 1991-01-25 1992-05-26 The Procter & Gamble Company Use of loperamide and related compounds for treatment of respiratory disease symptoms
US5225440A (en) * 1991-09-13 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5672988A (en) * 1994-04-15 1997-09-30 Linear Technology Corporation High-speed switching regulator drive circuit
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
AU6494798A (en) 1997-02-03 1998-08-25 Max-Delbruck-Centrum Fur Molekulare Medizin Genomic sequence of the human mu-opioid receptor gene and the variants, polymorphisms and mutations thereof
US6403602B1 (en) * 1997-02-20 2002-06-11 The University Of Kentucky Research Foundation Morphine-6-sulfate analogues and their use for the treatment of pain
US5976568A (en) * 1997-02-21 1999-11-02 Medical Doctors' Research Institute, Inc. Modular system of dietary supplement compositions for optimizing health benefits and methods
US6124282A (en) * 1997-05-22 2000-09-26 Sellers; Edward M. Drug formulations
AU1394899A (en) 1997-11-10 1999-05-31 Research Foundation Of The State University Of New York, The Opiate, cannabinoid, and estrogen receptors
US6914073B2 (en) * 1999-03-18 2005-07-05 Bristol Myers Squibb Company Vitamin formulation for cardiovascular health
WO2001008680A1 (de) * 1999-07-28 2001-02-08 Oswald Wiss Präparate mit sauerstoffsparender wirkung bei körperlicher leistung
JP4426083B2 (ja) * 2000-11-17 2010-03-03 日本碍子株式会社 炭化珪素質多孔体及びその製造方法
US20020193323A1 (en) * 2000-11-22 2002-12-19 Inna Yegorova Compositions and methods for promoting a healthy cardiovascular system and enhancing blood flow
US20030087896A1 (en) * 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20030219494A1 (en) * 2002-03-20 2003-11-27 Smith Maree Therese Compositions and methods of using them
US7323402B2 (en) * 2002-07-11 2008-01-29 International Rectifier Corporation Trench Schottky barrier diode with differential oxide thickness
CA2582346A1 (en) * 2004-10-01 2006-04-13 The Research Foundation Of State University Of New York Morphine and morphine precursors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6012001243; Ｎｅｕｒｏｂｉｏｌｏｇｙ　Ｄｉｓｅａｓｅ，（２００４），１６，ｐ．２４６-２５３ *
JPN6012001245; Ｂｒａｉｎ　Ｒｅｓｅａｒｃｈ，（１９９６），７２２，ｐ．１２５-１３１ *
JPN6012001246; Ｃｅｌｌ．Ｓｉｇｎａｌ．，（１９９９），１１（３），ｐ．１８９-１９３ *
JPN7012000090; Ｊｏｕｒｎａｌ　ｏｆ　Ｎｅｕｒｏｐｈｙｓｉｏｌｏｇｙ，（１９９７），７８（４），ｐ．２０７２-２０７８ *
JPN7012000091; Ｊｏｕｒｎａｌ　ｏｆ　Ｐａｒａｓｉｔｏｌｏｇｙ，（２００４），９０（１），ｐ．１５-２２ *
JPN7012000092; Ｊｏｕｒｎａｌ　ｏｆ　Ｐｈｙｓｉｏｌｏｇｙ　ａｎｄ　Ｐｈａｒｍａｃｏｌｏｇｙ，（２００４），５５（１，ＰａｒｔＩＩ），ｐ．２７９-２８８ *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US10857118B2 (en) 2013-10-22 2020-12-08 Yamo Pharmaceuticals Llc Compositions and methods for treating intestinal hyperpermeability
US11633372B2 (en) 2013-10-22 2023-04-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US11786496B2 (en) 2013-10-22 2023-10-17 Yamo Pharmaceuticals Llc Composition and methods for treating intestinal hyperpermeability
US12453709B2 (en) 2013-10-22 2025-10-28 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
JP2018511639A (ja) * 2015-04-14 2018-04-26 スティーブン・ホフマン 自閉症を治療するための組成物及び方法
US12150924B2 (en) 2018-07-19 2024-11-26 Yamo Pharmaceuticals Llc Compositions and methods for treating autism

Also Published As

Publication number Publication date
US9474749B2 (en) 2016-10-25
CA2582346A1 (en) 2006-04-13
US20110130356A1 (en) 2011-06-02
US8865696B2 (en) 2014-10-21
US20140128420A1 (en) 2014-05-08
US8481559B2 (en) 2013-07-09
EP1809283A2 (en) 2007-07-25
US20130309326A1 (en) 2013-11-21
US20140348953A1 (en) 2014-11-27
WO2006039691A2 (en) 2006-04-13
WO2006039691A3 (en) 2006-10-19
US20060088607A1 (en) 2006-04-27
US20080221143A1 (en) 2008-09-11
AU2005292184A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
US9474749B2 (en) Morphine and morphine precursors
Tuzim et al. An update on extra-oral bitter taste receptors
Frungieri et al. Direct effect of melatonin on Syrian hamster testes: melatonin subtype 1a receptors, inhibition of androgen production, and interaction with the local corticotropin-releasing hormone system
Diogenes et al. Prolactin modulates TRPV1 in female rat trigeminal sensory neurons
Kemp et al. Identification and functional characterization of melatonin Mel 1a receptors in pancreatic β cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling
Kumar et al. Disruption of LH-induced testosterone biosynthesis in testicular Leydig cells by triclosan: probable mechanism of action
Lennox et al. Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice
Müller et al. Selective activation of the hypothalamic vasopressinergic system in mice deficient for the corticotropin-releasing hormone receptor 1 is dependent on glucocorticoids
Takahashi et al. Blockade of adipocyte differentiation by cordycepin
Fu et al. Gut hormone GIP induces inflammation and insulin resistance in the hypothalamus
Silveira et al. cAMP‐dependent protein kinase inhibits FoxO activity and regulates skeletal muscle plasticity in mice
Börner et al. Comparative analysis of mu-opioid receptor expression in immune and neuronal cells
Miner Designer glucocorticoids
Tong et al. Mechanisms and novel therapeutic roles of bitter taste receptors in diseases
Znamensky et al. γ-Aminobutyric acid receptor subtype antagonists differentially alter opioid-induced feeding in the shell region of the nucleus accumbens in rats
Apostolakis et al. Pituitary adenylate cyclase-activating peptide: a pivotal modulator of steroid-induced reproductive behavior in female rodents
Salarinasab et al. Impact of morphine on the expression of insulin receptor and protein levels of insulin/IGFs in rat neural stem cells
Tokay et al. Beta‐amyloid peptide stimulates endozepine release in cultured rat astrocytes through activation of N‐formyl peptide receptors
Mazzocchi et al. Cholecystokinin (CCK) stimulates aldosterone secretion from human adrenocortical cells via CCK2 receptors coupled to the adenylate cyclase/protein kinase A signaling cascade
Contesse et al. Abnormal sensitivity of cortisol-producing adrenocortical adenomas to serotonin: in vivo and in vitro studies
Su et al. Steroid binding at σ receptors: CNS and immunological implications
Kanno et al. Nigramide c is a natural agonist of human pregnane x receptor
Lima Junior et al. Formoterol reduces muscle wasting in mice undergoing doxorubicin chemotherapy
US8241863B2 (en) Identification of an evolutionarily conserved pathway mediating transrepression of inflammatory response genes by nuclear receptors
Quintana et al. CD38: A Novel Modulator of Morphine Antinociception in the Spinal Cord

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120417

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120424

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121226